细胞收集和单采实践的趋势：来自收集和移植中心使用Spectra Optia的横断面研究的见解

IF 1.2 4区医学 Q4 HEMATOLOGY

Transfusion and Apheresis Science Pub Date : 2025-09-02 DOI:10.1016/j.transci.2025.104251

Nabih Azar , Nelson J. Chao , Manuel Cliquennois , Maria Geske , Tomoko Henzan , Tamarah Kent , Pascale Poullin , Tsiporah B. Shore , Matthew Cawson , Hugo Fabre , Franziska Waltl

{"title":"细胞收集和单采实践的趋势：来自收集和移植中心使用Spectra Optia的横断面研究的见解","authors":"Nabih Azar , Nelson J. Chao , Manuel Cliquennois , Maria Geske , Tomoko Henzan , Tamarah Kent , Pascale Poullin , Tsiporah B. Shore , Matthew Cawson , Hugo Fabre , Franziska Waltl","doi":"10.1016/j.transci.2025.104251","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>This study, conducted among collection and transplant centers in France, Germany, Japan, the United Kingdom (UK), and the United States (USA), aimed to better understand current trends, challenges, and future directions in cell collection and apheresis practices, focusing on the Spectra Optia™ Apheresis System.</div></div><div><h3>Methods</h3><div>This cross-sectional study was conducted from July to November 2023 among facilities using the Spectra Optia™ Apheresis System, which could also be using other comparable cell collection technologies, with expertise in cell collection and therapeutics. Respondents completed an online questionnaire.</div></div><div><h3>Results</h3><div>Forty-four facilities (France: 9, Germany: 7, Japan: 7, UK: 6, USA: 15) consented to participate. Across participating centers, a marked trend towards autologous cell collections was evident in France (mean: 71 % of collections were for autologous purposes), Germany (74 %), UK (79 %), and USA (73 %). Among centers in Japan, a more balanced division between autologous (47 %) and allogeneic (53 %) collections was seen. Over half of all respondents indicated facing several key challenges, including issues related to supporting services, patients, logistics, purity, and technology. The respondents largely agreed that the cell therapy demand will increase over the next 3–5 years and estimated a growth of 10–200 %.</div></div><div><h3>Conclusions</h3><div>This study highlights the breadth of indications for which Spectra Optia is used, and the dynamic nature and growth prospects of the field. Innovation and standardization in apheresis technologies will be important to drive the potential of cell-based therapeutics.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 6","pages":"Article 104251"},"PeriodicalIF":1.2000,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Trends in cell collection and apheresis practices: Insights from a cross-sectional study on the use of Spectra Optia in collection and transplant centers\",\"authors\":\"Nabih Azar , Nelson J. Chao , Manuel Cliquennois , Maria Geske , Tomoko Henzan , Tamarah Kent , Pascale Poullin , Tsiporah B. Shore , Matthew Cawson , Hugo Fabre , Franziska Waltl\",\"doi\":\"10.1016/j.transci.2025.104251\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>This study, conducted among collection and transplant centers in France, Germany, Japan, the United Kingdom (UK), and the United States (USA), aimed to better understand current trends, challenges, and future directions in cell collection and apheresis practices, focusing on the Spectra Optia™ Apheresis System.</div></div><div><h3>Methods</h3><div>This cross-sectional study was conducted from July to November 2023 among facilities using the Spectra Optia™ Apheresis System, which could also be using other comparable cell collection technologies, with expertise in cell collection and therapeutics. Respondents completed an online questionnaire.</div></div><div><h3>Results</h3><div>Forty-four facilities (France: 9, Germany: 7, Japan: 7, UK: 6, USA: 15) consented to participate. Across participating centers, a marked trend towards autologous cell collections was evident in France (mean: 71 % of collections were for autologous purposes), Germany (74 %), UK (79 %), and USA (73 %). Among centers in Japan, a more balanced division between autologous (47 %) and allogeneic (53 %) collections was seen. Over half of all respondents indicated facing several key challenges, including issues related to supporting services, patients, logistics, purity, and technology. The respondents largely agreed that the cell therapy demand will increase over the next 3–5 years and estimated a growth of 10–200 %.</div></div><div><h3>Conclusions</h3><div>This study highlights the breadth of indications for which Spectra Optia is used, and the dynamic nature and growth prospects of the field. Innovation and standardization in apheresis technologies will be important to drive the potential of cell-based therapeutics.</div></div>\",\"PeriodicalId\":49422,\"journal\":{\"name\":\"Transfusion and Apheresis Science\",\"volume\":\"64 6\",\"pages\":\"Article 104251\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2025-09-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Transfusion and Apheresis Science\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1473050225001892\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion and Apheresis Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1473050225001892","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

本研究在法国、德国、日本、英国和美国的采集和移植中心进行，旨在更好地了解细胞采集和单采实践的当前趋势、挑战和未来方向，重点关注Spectra Optia™单采系统。本横断面研究于2023年7月至11月在使用Spectra Optia™Apheresis系统的设备中进行，该系统也可以使用其他具有细胞收集和治疗专业知识的类似细胞收集技术。受访者完成了一份在线问卷。结果44家机构（法国9家、德国7家、日本7家、英国6家、美国15家）同意参与。在参与的中心中，法国（平均：71 %的收集用于自体目的）、德国（74 %）、英国（79 %）和美国（73 %）的自体细胞收集趋势明显。在日本的研究中心，自体（47% %）和同种异体（53% %）标本的分布更为平衡。超过一半的受访者表示面临几个关键挑战，包括与支持服务、患者、物流、纯度和技术相关的问题。受访者普遍认为，细胞治疗需求将在未来3-5年内增加，预计增长率为10 - 200 %。本研究突出了Spectra Optia用于适应症的广度，以及该领域的动态性质和增长前景。分离技术的创新和标准化对于推动细胞治疗的潜力至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Trends in cell collection and apheresis practices: Insights from a cross-sectional study on the use of Spectra Optia in collection and transplant centers

Background

This study, conducted among collection and transplant centers in France, Germany, Japan, the United Kingdom (UK), and the United States (USA), aimed to better understand current trends, challenges, and future directions in cell collection and apheresis practices, focusing on the Spectra Optia™ Apheresis System.

Methods

This cross-sectional study was conducted from July to November 2023 among facilities using the Spectra Optia™ Apheresis System, which could also be using other comparable cell collection technologies, with expertise in cell collection and therapeutics. Respondents completed an online questionnaire.

Results

Forty-four facilities (France: 9, Germany: 7, Japan: 7, UK: 6, USA: 15) consented to participate. Across participating centers, a marked trend towards autologous cell collections was evident in France (mean: 71 % of collections were for autologous purposes), Germany (74 %), UK (79 %), and USA (73 %). Among centers in Japan, a more balanced division between autologous (47 %) and allogeneic (53 %) collections was seen. Over half of all respondents indicated facing several key challenges, including issues related to supporting services, patients, logistics, purity, and technology. The respondents largely agreed that the cell therapy demand will increase over the next 3–5 years and estimated a growth of 10–200 %.

Conclusions

This study highlights the breadth of indications for which Spectra Optia is used, and the dynamic nature and growth prospects of the field. Innovation and standardization in apheresis technologies will be important to drive the potential of cell-based therapeutics.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Transfusion and Apheresis Science 医学-血液学

CiteScore

3.60

自引率

5.30%

发文量

181

审稿时长

42 days

期刊介绍： Transfusion and Apheresis Science brings comprehensive and up-to-date information to physicians and health care professionals involved in the rapidly changing fields of transfusion medicine, hemostasis and apheresis. The journal presents original articles relating to scientific and clinical studies in the areas of immunohematology, transfusion practice, bleeding and thrombotic disorders and both therapeutic and donor apheresis including hematopoietic stem cells. Topics covered include the collection and processing of blood, compatibility testing and guidelines for the use of blood products, as well as screening for and transmission of blood-borne diseases. All areas of apheresis - therapeutic and collection - are also addressed. We would like to specifically encourage allied health professionals in this area to submit manuscripts that relate to improved patient and donor care, technical aspects and educational issues. Transfusion and Apheresis Science features a "Theme" section which includes, in each issue, a group of papers designed to review a specific topic of current importance in transfusion and hemostasis for the discussion of topical issues specific to apheresis and focuses on the operators'' viewpoint. Another section is "What''s Happening" which provides informal reporting of activities in the field. In addition, brief case reports and Letters to the Editor, as well as reviews of meetings and events of general interest, and a listing of recent patents make the journal a complete source of information for practitioners of transfusion, hemostasis and apheresis science. Immediate dissemination of important information is ensured by the commitment of Transfusion and Apheresis Science to rapid publication of both symposia and submitted papers.